LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,266
تعداد مقالات11,540
تعداد مشاهده مقاله81,960,921
تعداد دریافت فایل اصل مقاله121,091,853
Mehmandoostli, Zohreh, Dehghani Ashkezari, Mahmood, Seifati, Seyed Morteza, Kardar, Gholam Ali. (1405). Integrated Transcriptomic Analysis Identifies a Six-Gene Prognostic Signature, RNA Editing Derived Neoantigens, and miRNA Regulatory Networks in Renal Cell Carcinoma. سامانه مدیریت نشریات علمی, (), -. doi: 10.30476/ijms.2026.108742.4376
Zohreh Mehmandoostli; Mahmood Dehghani Ashkezari; Seyed Morteza Seifati; Gholam Ali Kardar. "Integrated Transcriptomic Analysis Identifies a Six-Gene Prognostic Signature, RNA Editing Derived Neoantigens, and miRNA Regulatory Networks in Renal Cell Carcinoma". سامانه مدیریت نشریات علمی, , , 1405, -. doi: 10.30476/ijms.2026.108742.4376
Mehmandoostli, Zohreh, Dehghani Ashkezari, Mahmood, Seifati, Seyed Morteza, Kardar, Gholam Ali. (1405). 'Integrated Transcriptomic Analysis Identifies a Six-Gene Prognostic Signature, RNA Editing Derived Neoantigens, and miRNA Regulatory Networks in Renal Cell Carcinoma', سامانه مدیریت نشریات علمی, (), pp. -. doi: 10.30476/ijms.2026.108742.4376
Mehmandoostli, Zohreh, Dehghani Ashkezari, Mahmood, Seifati, Seyed Morteza, Kardar, Gholam Ali. Integrated Transcriptomic Analysis Identifies a Six-Gene Prognostic Signature, RNA Editing Derived Neoantigens, and miRNA Regulatory Networks in Renal Cell Carcinoma. سامانه مدیریت نشریات علمی, 1405; (): -. doi: 10.30476/ijms.2026.108742.4376

Integrated Transcriptomic Analysis Identifies a Six-Gene Prognostic Signature, RNA Editing Derived Neoantigens, and miRNA Regulatory Networks in Renal Cell Carcinoma

Iranian Journal of Medical Sciences
مقالات آماده انتشار، اصلاح شده برای چاپ، انتشار آنلاین از تاریخ 15 اردیبهشت 1405    اصل مقاله (5.17 M)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2026.108742.4376
نویسندگان
Zohreh Mehmandoostli1، 2؛ Mahmood Dehghani Ashkezari1، 2؛ Seyed Morteza Seifati1، 2؛ Gholam Ali Kardar* 3، 4
1Department of Biology, Ashk.C., Islamic Azad University, Ashkezar, Iran
2Medical Biotechnology Research Center, Ashk.C., Islamic Azad University, Ashkezar, Iran
3Immunology, Asthma and Allergy Research Institute (IAARI), Tehran University of Medical Sciences, Tehran, Iran
4Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
چکیده
Background: Renal cell carcinoma (RCC) is a heterogeneous malignancy with variable outcomes and limited biomarkers for prognosis or immunotherapy response. Although mutations in VHL, SETD2, PBRM1, BAP1, FLCN, and TP53 are frequent, their integrated effects on tumor biology, RNA editing, and non-coding RNA regulation remain unclear. This study aims to integrate genetic, epigenetic, and immune features to provide mechanistic insights into RCC progression and support precision immuno-oncology and vaccine development.
Methods: Transcriptomic data from TCGA-KIRC and four Gene Expression Omnibus (GEO) cohorts were normalized, batch-corrected, and integrated. Differentially expressed genes were analyzed using LASSO-Cox regression, Kaplan–Meier survival, ROC curves, and nomogram modeling. RNA editing events from REDIportal were annotated for nonsynonymous substitutions and assessed for human leukocyte antigen (HLA) class I binding. Parallel miRNA–mRNA analyses identified regulatory interactions. Functional enrichment and immune LASSO deconvolution were used to explore pathways and tumor microenvironment features.
Results: VHL, SETD2, and BAP1 were downregulated, while FLCN showed heterogeneous upregulation. A six-gene prognostic signature (BAP1, SETD2, TP53, PBRM1, FLCN, VHL) stratified patients into high- and low-risk groups with AUCs>0.70 at 1, 3, and 5 years. RNA editing revealed 35 recurrent events, including 25 nonsynonymous substitutions in TP53, BAP1, and SETD2. Predicted neoantigens included both broadly presented and population-specific epitopes. Deregulated miRNAs highlighted post-transcriptional regulation influencing progression and immune evasion. Functional enrichment analysis implicated chromatin remodeling, metabolism, and immune regulation, while immune profiling linked BAP1 mutations with reduced NK/Treg infiltration and identified chromatin genes associated with endothelial and immune activity.
Conclusion: This integrative study identifies a six-gene signature, recurrent RNA editing–derived neoantigens, and miRNA networks in RCC. By connecting genomic, epigenetic, and immune features, it provides mechanistic insights into RCC progression and supports precision immuno-oncology and vaccine development.

تازه های تحقیق

Zohreh Mehmandoostli (Google Scholar)
Gholam Ali Kardar (Google Scholar)

کلیدواژه‌ها
Carcinoma, renal cell؛ RNA editing؛ Biomarkers؛ Prognosis؛ Antigens
مراجع
  1. Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, et al. Epidemiology of Renal Cell Carcinoma. World J Oncol. 2020;11:79-87. doi: 10.14740/wjon1279. PubMed PMID: 32494314; PubMed Central PMCID: PMC7239575.
  2. Li J, Luo P, Liu S, Fu M, Lin A, Liu Y, et al. Effective strategies to enhance the diagnosis and treatment of RCC: The application of biocompatible materials. Mater Today Bio. 2024;27:101149. doi: 10.1016/j.mtbio.2024.101149. PubMed PMID: 39100279; PubMed Central PMCID: PMC11296058.
  3. Xie D, Li G, Zheng Z, Zhang X, Wang S, Jiang B, et al. The molecular code of kidney cancer: A path of discovery for gene mutation and precision therapy. Mol Aspects Med. 2025;101:101335. doi: 10.1016/j.mam.2024.101335. PubMed PMID: 39746268.
  4. Kim E, Zschiedrich S. Renal Cell Carcinoma in von Hippel-Lindau Disease-From Tumor Genetics to Novel Therapeutic Strategies. Front Pediatr. 2018;6:16. doi: 10.3389/fped.2018.00016. PubMed PMID: 29479523; PubMed Central PMCID: PMC5811471.
  5. Sumiyoshi T, Yamasaki T, Takeda M, Mizuno K, Utsunomiya N, Sakamoto H, et al. Detection of von Hippel-Lindau gene mutation in circulating cell-free DNA for clear cell renal cell carcinoma. Cancer Sci. 2021;112:3363-74. doi: 10.1111/cas.14972. PubMed PMID: 34009695; PubMed Central PMCID: PMC8353948.
  6. Mazumder S, Higgins PJ, Samarakoon R. Downstream Targets of VHL/HIF-α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance. Cancers (Basel). 2023;15. doi: 10.3390/cancers15041316. PubMed PMID: 36831657; PubMed Central PMCID: PMC9953937.
  7. Bihr S, Ohashi R, Moore AL, Rüschoff JH, Beisel C, Hermanns T, et al. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma. Neoplasia. 2019;21:247-56. doi: 10.1016/j.neo.2018.12.006. PubMed PMID: 30660076; PubMed Central PMCID: PMC6355619.
  8. Walton J, Lawson K, Prinos P, Finelli A, Arrowsmith C, Ailles L. PBRM1, SETD2 and BAP1 - the trinity of 3p in clear cell renal cell carcinoma. Nat Rev Urol. 2023;20:96-115. doi: 10.1038/s41585-022-00659-1. PubMed PMID: 36253570.
  9. Croessmann S, Wong HY, Zabransky DJ, Chu D, Rosen DM, Cidado J, et al. PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity. Breast Cancer Res Treat. 2017;162:451-64. doi: 10.1007/s10549-017-4147-2. PubMed PMID: 28190247; PubMed Central PMCID: PMC6100768.
  10. Lu YR, Yuan Q, Liu J, Han X, Liu M, Liu QQ, et al. A rare occurrence of a hereditary Birt-Hogg-Dubé syndrome: A case report. World J Clin Cases. 2021;9:7123-32. doi: 10.12998/wjcc.v9.i24.7123. PubMed PMID: 34540968; PubMed Central PMCID: PMC8409184.
  11. Mai TL, Chuang TJ. A-to-I RNA editing contributes to the persistence of predicted damaging mutations in populations. Genome Res. 2019;29:1766-76. doi: 10.1101/gr.246033.118. PubMed PMID: 31515285; PubMed Central PMCID: PMC6836733.
  12. Zhang S, Xiao X, Yi Y, Wang X, Zhu L, Shen Y, et al. Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets. Signal Transduct Target Ther. 2024;9:149. doi: 10.1038/s41392-024-01848-7. PubMed PMID: 38890350; PubMed Central PMCID: PMC11189549.
  13. Kurkowiak M, Arcimowicz Ł, Chruściel E, Urban-Wójciuk Z, Papak I, Keegan L, et al. The effects of RNA editing in cancer tissue at different stages in carcinogenesis. RNA Biol. 2021;18:1524-39. doi: 10.1080/15476286.2021.1877024. PubMed PMID: 33593231; PubMed Central PMCID: PMC8582992.
  14. Wang Z, Gu Y, Sun X, Huang H. Computation strategies and clinical applications in neoantigen discovery towards precision cancer immunotherapy. Biomark Res. 2025;13:96. doi: 10.1186/s40364-025-00808-9. PubMed PMID: 40629481; PubMed Central PMCID: PMC12239460.
  15. Richard G, Princiotta MF, Bridon D, Martin WD, Steinberg GD, De Groot AS. Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy. Expert Rev Vaccines. 2022;21:173-84. doi: 10.1080/14760584.2022.2012456. PubMed PMID: 34882038.
  16. Roerden M, Castro AB, Cui Y, Harake N, Kim B, Dye J, et al. Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression. J Immunother Cancer. 2024;12. doi: 10.1136/jitc-2024-010249. PubMed PMID: 39521615; PubMed Central PMCID: PMC11552027.
  17. Shirole NH, Kaelin WG, Jr. von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology. Hematol Oncol Clin North Am. 2023;37:809-25. doi: 10.1016/j.hoc.2023.04.011. PubMed PMID: 37270382; PubMed Central PMCID: PMC11315268.
  18. Ma C, Liu M, Feng W, Rao H, Zhang W, Liu C, et al. Loss of SETD2 aggravates colorectal cancer progression caused by SMAD4 deletion through the RAS/ERK signalling pathway. Clin Transl Med. 2023;13:e1475. doi: 10.1002/ctm2.1475. PubMed PMID: 37962020; PubMed Central PMCID: PMC10644329.
  19. Wang H, Guo M, Wei H, Chen Y. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct Target Ther. 2023;8:92. doi: 10.1038/s41392-023-01347-1. PubMed PMID: 36859359; PubMed Central PMCID: PMC9977964.
  20. Shigaki H, Baba Y, Watanabe M, Murata A, Ishimoto T, Iwatsuki M, et al. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. Clin Cancer Res. 2013;19:2451-9. doi: 10.1158/1078-0432.ccr-12-3559. PubMed PMID: 23532889.
  21. Yang X, Chen R, Chen Y, Zhou Y, Wu C, Li Q, et al. Methyltransferase SETD2 inhibits tumor growth and metastasis via STAT1-IL-8 signaling-mediated epithelial-mesenchymal transition in lung adenocarcinoma. Cancer Sci. 2022;113:1195-207. doi: 10.1111/cas.15299. PubMed PMID: 35152527; PubMed Central PMCID: PMC8990294.
  22. Qayoom H, Haq BU, Sofi S, Jan N, Jan A, Mir MA. Targeting mutant p53: a key player in breast cancer pathogenesis and beyond. Cell Commun Signal. 2024;22:484. doi: 10.1186/s12964-024-01863-9. PubMed PMID: 39390510; PubMed Central PMCID: PMC11466041.
  23. Hudler P, Urbancic M. The Role of VHL in the Development of von Hippel-Lindau Disease and Erythrocytosis. Genes (Basel). 2022;13. doi: 10.3390/genes13020362. PubMed PMID: 35205407; PubMed Central PMCID: PMC8871608.
  24. Zhang H, Xu J, Long Y, Maimaitijiang A, Su Z, Li W, et al. Unraveling the Guardian: p53’s Multifaceted Role in the DNA Damage Response and Tumor Treatment Strategies. Int J Mol Sci. 2024;25. doi: 10.3390/ijms252312928. PubMed PMID: 39684639; PubMed Central PMCID: PMC11641486.
  25. Feng T, Zhao J, Wei D, Guo P, Yang X, Li Q, et al. Immunogenomic Analyses of the Prognostic Predictive Model for Patients With Renal Cancer. Front Immunol. 2021;12:762120. doi: 10.3389/fimmu.2021.762120. PubMed PMID: 34712244; PubMed Central PMCID: PMC8546215.
  26. Zhang Y, Li L, Mendoza JJ, Wang D, Yan Q, Shi L, et al. Advances in A-to-I RNA editing in cancer. Mol Cancer. 2024;23:280. doi: 10.1186/s12943-024-02194-6. PubMed PMID: 39731127; PubMed Central PMCID: PMC11673720.
  27. Li X, You J, Hong L, Liu W, Guo P, Hao X. Neoantigen cancer vaccines: a new star on the horizon. Cancer Biol Med. 2023;21:274-311. doi: 10.20892/j.issn.2095-3941.2023.0395. PubMed PMID: 38164734; PubMed Central PMCID: PMC11033713.
  28. Ding YP, Liu CC, Yu KD. RNA modifications in the tumor microenvironment: insights into the cancer-immunity cycle and beyond. Exp Hematol Oncol. 2025;14:48. doi: 10.1186/s40164-025-00648-1. PubMed PMID: 40176140; PubMed Central PMCID: PMC11963313.
  29. Mehmandoostli Z, Ashkezari MD, Seifati SM, Farzin A, Kardar GA. Exploring neoantigens and genetic profiles in renal cell carcinoma: a study of Iranian patients. J Curr Oncol Med Sci. 2025;5:1103-14.
  30. Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, Leng N, Pavía-Jiménez A, Wang S, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet. 2012;44:751-9. doi: 10.1038/ng.2323. PubMed PMID: 22683710; PubMed Central PMCID: PMC3788680.
  31. Page PM, Dastous SA, Richard PO, Pavic M, Nishimura T, Riazalhosseini Y, et al. MicroRNA profiling identifies VHL/HIF-2α dependent miR-2355-5p as a key modulator of clear cell Renal cell carcinoma tumor growth. Cancer Cell Int. 2025;25:71. doi: 10.1186/s12935-025-03711-3. PubMed PMID: 40016765; PubMed Central PMCID: PMC11869434.
  32. Yang W, Ma J, Zhou W, Cao B, Zhou X, Zhang H, et al. Reciprocal regulations between miRNAs and HIF-1α in human cancers. Cell Mol Life Sci. 2019;76:453-71. doi: 10.1007/s00018-018-2941-6. PubMed PMID: 30317527; PubMed Central PMCID: PMC11105242.
  33. Peng S, Xie Z, Jiang H, Zhang G, Chen N. Revealing the characteristics of SETD2-mutated clear cell renal cell carcinoma through tumor heterogeneity analysis. Front Genet. 2024;15:1447139. doi: 10.3389/fgene.2024.1447139. PubMed PMID: 39119581; PubMed Central PMCID: PMC11306021.
  34. Zamora-Fuentes JM, Hernández-Lemus E, Espinal-Enríquez J. Methylation-related genes involved in renal carcinoma progression. Front Genet. 2023;14:1225158. doi: 10.3389/fgene.2023.1225158. PubMed PMID: 37693315; PubMed Central PMCID: PMC10486271.
  35. Liu T, Xia Q, Zhang H, Wang Z, Yang W, Gu X, et al. CCL5-dependent mast cell infiltration into the tumor microenvironment in clear cell renal cell carcinoma patients. Aging (Albany NY). 2020;12:21809-36. doi: 10.18632/aging.103999. PubMed PMID: 33177244; PubMed Central PMCID: PMC7695370.
  36. Xu D, Gao Y, Yang H, Spils M, Marti TM, Losmanová T, et al. BAP1 Deficiency Inflames the Tumor Immune Microenvironment and Is a Candidate Biomarker for Immunotherapy Response in Malignant Pleural Mesothelioma. JTO Clin Res Rep. 2024;5:100672. doi: 10.1016/j.jtocrr.2024.100672. PubMed PMID: 38715965; PubMed Central PMCID: PMC11070913.
  37. Chang H, Li M, Zhang L, Li M, Ong SH, Zhang Z, et al. Loss of histone deubiquitinase Bap1 triggers anti-tumor immunity. Cell Oncol (Dordr). 2025;48:183-203. doi: 10.1007/s13402-024-00978-y. PubMed PMID: 39141316; PubMed Central PMCID: PMC11850471.
  38. Zhang A, Miao K, Sun H, Deng CX. Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. Int J Biol Sci. 2022;18:3019-33. doi: 10.7150/ijbs.72534. PubMed PMID: 35541919; PubMed Central PMCID: PMC9066118.
آمار
تعداد مشاهده مقاله: 14
تعداد دریافت فایل اصل مقاله: 40


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب